What is Cellectis?
Founded in 1999 and headquartered in Paris, France, Cellectis operates at the intersection of biotechnology and pharmaceutical manufacturing. The company is recognized for its specialized focus on developing innovative therapies, leveraging a robust technology infrastructure that spans both European and North American markets. As a publicly traded entity since 2019, Cellectis maintains a dual-market presence, integrating sophisticated B2B and B2C strategies to advance its clinical programs. The firm's commitment to pharmaceutical excellence is supported by a diverse portfolio of intellectual property and a strategic approach to life sciences innovation.
How much funding has Cellectis raised?
Cellectis has raised a total of $521.5M across 5 funding rounds:
Corporate Investment
$22.2M
Stock Offering
$129M
Stock Offering
$163.7M
Other Financing Round
$164M
Debt
$42.6M
Corporate Investment (2014): $22.2M with participation from Merlin Nexus, Ridgeback Capital, OrbiMed, venBio, and Aquilo Capital Management
Stock Issuance/Offering (2015): $129M led by Undisclosed
Stock Issuance/Offering (2018): $163.7M supported by Barclays, Goldman Sachs & Co, and Citigroup
Other Financing Round (2018): $164M featuring Undisclosed
Debt (2022): $42.6M backed by European Investment Bank
Key Investors in Cellectis
Barclays
Barclays PLC is a British multinational universal bank providing a comprehensive suite of financial services, including corporate and investment banking, to global institutions.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused exclusively on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms.
venBio
venBio is a life sciences investment firm that partners with industry leaders to develop innovative medicines, focusing on novel therapeutics for unmet medical needs.
What's next for Cellectis?
Looking ahead, the recent capital infusion positions Cellectis to accelerate its clinical development milestones and optimize its manufacturing capabilities. By leveraging the support of major financial institutions and specialized life sciences investors, the company is well-equipped to navigate the complexities of the regulatory environment and scale its therapeutic offerings. Future growth will likely center on expanding its pipeline of novel treatments, enhancing its digital health infrastructure, and fostering strategic partnerships that align with its mission to address significant unmet medical needs through precision medicine.
See full Cellectis company page
